To search for a molecular therapeutic target for BHD-associated kidney cancer, we compared DEGs identified in BHD-associated kidney cancers with DEGs in other cancers analyzed in this study, and found that MET was highly expressed in BHD-associated kidney cancers (Figure 5C). Here, MET is linked to kidney cancer.